00:00In terms of prevention, we are mainly focused on subjects who have already undergone an acute ischemic cardiovascular event.
00:11It may have been a myocardial infarction or an ischemic ictus.
00:15On this very high-risk population, we know very well what to do.
00:20There is a strong awareness of how to intervene and what are the lipidinological targets for cholesterol and LDL in particular to reach.
00:29Therefore, I would say that on this group of patients, most of the attention that is due is put on the field.
00:37On the other hand, there is a very large and even more numerous population group that is at very high risk and has fortunately never undergone an acute cardiovascular event.
00:49The challenge for the prevention of tomorrow and already of today is to intervene on this pool of subjects that we know very well who they are.
01:00Thanks to the European guidelines on prevention, these subjects are well identified for groups of populations in relation to the presence, for example,
01:11of ischemic pathologies, whether coronary, carotid, peripheral arterial vases, clinical or subclinical, but which have not yet generated acute events.
01:22We have to treat these patients and we can also treat them in a refundable regime as best we can for the containment of the lipid risk and not only.
01:33Obviously, this is for our activity as cardiologists the topic that today has become central, I would say, for the future strategy of cardiovascular prevention.
01:47The new cultural approach is to overcome the dichotomy between primary and secondary prevention,
01:54because above all the term primary prevention implies a false idea of low cardiovascular risk and therefore in a certain way of reassuring subjects,
02:06even unfortunately of those who, although they have not received events, have more or less the same risk as those who have already received them.
02:13We should think in terms of cardiovascular risk categories, especially for the lipid targets that I want to emphasize.
02:21It is the only risk factor that is targeted in terms of values to be achieved in relation to the four categories of cardiovascular risk.
02:30We have already done a very important thing together with the Italian Society of Clinical Biologists.
02:37We have made it possible, with a consent document that is also promoted in the reports, and we are already seeing it,
02:43an assessment of cholesterol that does not indicate for everyone a term of presumed normality,
02:52but that, vice versa, indicates a term of desirable cholesterol,
02:58referring for each individual to their own cardiovascular risk level.
03:05And this is very important.
Comments